Long-course venetoclax with hypomethylating agents in unfit AML patients shows stable efficacy and MRD prognostic value.

This single-center retrospective analysis assessed long-course venetoclax combined with hypomethylating agents in unfit AML patients. The sample size was not reported, and follow-up duration was not reported. The study setting was single-center. Study phase was not reported.

The intervention involved long-course venetoclax combined with hypomethylating agents. No comparator was reported. Clinical efficacy was stable, and disease remission was effectively achieved. MRD negativity was closely associated with better prognosis, whereas higher recurrence risk was noted. Secondary outcomes included efficacy, safety, and prognostic value of measurable residual disease. Correlation between dynamic MRD changes and patient prognosis was assessed.

Safety included hematological and infectious non-hematological toxicity with controllable overall safety. Serious adverse events were not reported. Limitations include single-center design, limited sample size, absence of a short-course control group, and survivorship bias should be considered. Survivorship bias should be considered in interpretation.

Practice relevance involves providing evidence for optimizing clinical low-intensity treatment regimens. Causal conclusions about treatment duration cannot be drawn. Conclusions require validation by larger multicenter prospective studies. Generalizability is limited due to single-center design and limited sample size. Funding or conflicts were not reported. Do not overstate causal conclusions about treatment duration. Certainty requires external validation.